InsidersTradesSigma
Track the Croda International Plc stock price and the full directors' dealings record of the company, a publicly traded company based in United Kingdom. Shares are listed on the UK market, under the authority of RNS (LSE). Operating in the Chemicals & Materials sector, Croda International Plc has logged 135 insider filings. Market capitalisation: €3.8bn. The latest transaction was filed on 9 September 2026 (Grant). Among the most active insiders: 1) Stephen Edward Foots 2) Mrs Sandra Elaine Breene 3) Thomas Michael Brophy 4) David Timothy Cherry 5) Anthony Damien Fitzpatrick 6) Mark William Robinson 7) Ritesh Tanna. Every trade is accessible without an account.
135
Insider Decl.
n/a
Thresholds
€234m
82 ops.
Buy Volume
€32m
25 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Croda International Plc Buy (bullish), based on 13 analysts. Average price target: £3,634.62.
44Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 17,699 of 29,064 companies
45.4
score / 100
Value45
Quality46
FCF yld4.4%
Earn yld1.7%
EV/EBITDA17.4x
ROE3.7%
Gross mgn44%
Net mgn3.6%
Debt/EBITDA2.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 September 2026
Declarations135 total
325 shares@ £26.37N/A - Grant of an optionISIN GB00BJFFLV09RNS:9763360
4,176 shares@ £75.11310.0084% mcap22.6% of flowXLONISIN GB00BJFFLV09RNS:9710715
4,176 shares@ £232.140.026% mcap90.4% of flowXLONISIN GB00BJFFLV09FCA-NSM:d2d3d375-d124-46cf-8557-16f6123078dd
1,890 shares@ £33.03650.0017% mcap21.2% of flowXLONISIN GB00BJFFLV09RNS:9699016
●
440 shares@ £47,859.500.56% mcap69.3% of flowXLONISIN GB00BJFFLV09RNS:9666054
●
0XLONISIN GB00BJFFLV09RNS:81150c53-f71a-48c4-b1ff-3fd133b56cc3
●
22,383 shares@ £422.3010.26% mcap100.0% of flowXLONISIN GB00BJFFLV09RNS:9614272
●
0XLONISIN GB00BJFFLV09RNS:486d7712-882f-4315-be30-04218def9963
1,516 shares@ £74.46450.0031% mcap24.4% of flowXLONISIN GB00BJFFLV09RNS:9595377
1,516 shares@ £230.16080.0095% mcap75.6% of flowXLONISIN GB00BJFFLV09RNS:11f2fbff-c828-4e07-86ca-00a1778d0225
3,801 shares@ £30.364650.0% of flowXLONISIN GB00BJFFLV09RNS:9592620
323 shares@ £182.49130.0016% mcap44.2% of flowXLONISIN GB00BJFFLV09RNS:9592636
77 shares@ £30.37750.0001% mcap2.2% of flowXLONISIN GB00BJFFLV09RNS:9592773
5 shares@ £30.3420.0000% mcap0.0% of flowXLONISIN GB00BJFFLV09RNS:7a75bbdb-67b2-419e-9d92-2a5874fe8472
77 shares@ £30.37750.0001% mcap2.2% of flowXLONISIN GB00BJFFLV09RNS:4ee0cce3-d66c-4c05-88c7-5ab1fbec4b0a
42 shares@ £30.16930.0000% mcap1.2% of flowXLONISIN GB00BJFFLV09RNS:b73fcde0-a3b7-4bbc-9f27-824458fc84db
323 shares@ £230.16930.0020% mcap55.8% of flowXLONISIN GB00BJFFLV09RNS:a4b6ad68-0c4e-4b89-af08-d52808f1117e
5 shares@ £230.8320.0000% mcap50.0% of flowXLONISIN GB00BJFFLV09RNS:f3fcd66d-ec91-42b4-ba7c-941561df2174
5 shares@ £30.3420.0000% mcap0.0% of flowXLONISIN GB00BJFFLV09RNS:9592877
42 shares@ £30.16930.0000% mcap1.2% of flowXLONISIN GB00BJFFLV09RNS:9592637
442 shares@ £27.5367100.0% of flowXLONISIN GB00BJFFLV09RNS:9570732
442 shares@ £27.53670.0003% mcap0.3% of flowXLONISIN GB00BJFFLV09RNS:a565cd80-66cc-4285-b6e5-6d91f9b73e04
●
0XLONISIN GB00BJFFLV09RNS:e169c586-ce3c-47cf-a8db-7b302ad21d21
224 shares@ £228.400.0014% mcap0.4% of flowXLONISIN GB00BJFFLV09RNS:f56e0c14-68b7-478d-891c-0c5a1d835a07
25 of 135 declarations
关于 Croda International Plc
Croda International Plc 是一家总部位于英国的特种化学品集团，在伦敦证券交易所（富时 100/250/AIM）上市。该公司以“智能科学”为定位：它开发高性能成分和解决方案，供工业客户和消费品牌用于功能性、质量和可持续性至关重要的配方中。Croda 成立于 1925 年，于 2025 年庆祝其百年华诞，这凸显了其悠久的运营历史和深厚的技术传承。其全球总部位于约克郡的 Cowick Hall，靠近其最初的 Rawcliffe Bridge 基地，该基地仍然是该公司在英国的制造地点之一。 Croda 的商业模式围绕三个主要部门组织。消费者护理部门服务于最接近终端消费者的市场，包括美容、个人护理、家庭护理和香料成分。生命科学部门涵盖制药、更广泛的生命科学和农业领域，提供从赋形剂和药物输送系统到作物保护和种子增强技术等解决方案。工业特种产品部门则面向更具技术性的市场，如涂料、水处理、纺织品、纤维和精选的配方密集型工业应用。这种组合减少了对任何单一终端市场的依赖，同时提供了对可持续创新、健康和配方效率等长期主题的敞口。 从竞争角度来看，Croda 通过其科学专业化、应用主导的创新和紧密的客户关系而脱颖而出。这种组合帮助该集团在技术要求高且转换成本可能很高的利基市场中建立强大的地位。Croda 强调差异化产品以及与客户的协作开发，尤其是在上市速度、性能和法规遵从性至关重要的市场中。 从地理上看，Croda 拥有广泛的全球足迹，在多个国家开展业务，并在英国、欧洲、北美和亚洲拥有重要的制造、研发和商业活动。英国仍然具有战略重要性，拥有制造、分销、金融和专业实验室能力。最近的亮点包括 2025 年在宾夕法尼亚州开设新的脂质生产设施以支持其制药战略，发布 2025 年全年业绩显示出改善的势头，以及持续的运营简化和利润提升举措。该公司还在 2025 年任命了一位新的首席财务官，这凸显了运营和领导层转型活跃的阶段。
